biotech

Podcasts

High Growth Comes With Risk in Biotech ETF Space (Podcast)

By Brenton GarenSeptember 9, 2016

Equity ETFs

For Biotech ETFs, It’s All About U.S. Presidential Politics

By Tom LydonSeptember 1, 2016

Equity ETFs

Reading Market Tea Leaves With a Big Biotech ETF

By Tom LydonAugust 10, 2016

Equity ETFs

More Support for Biotech ETFs as Value Plays

By Tom LydonAugust 8, 2016

Equity ETFs

Amid Biotech Rally, Investors Show Jitters

By Tom LydonAugust 4, 2016

Equity ETFs

Surprising Value in Big Biotech ETFs

By Brenton GarenJuly 21, 2016

Equity ETFs

Biotech ETFs are at a Crucial Technical Juncture

By Tom LydonJuly 18, 2016

Equity ETFs

Brexit: A Bane for Bumbling Biotech ETFs?

By Tom LydonJune 28, 2016

Equity ETFs

A Technical Test For A Big Biotech ETF

By Tom LydonMay 26, 2016

Equity ETFs

Pfizer Acquires Anacor, Reviving M&A Bets in Biotech Sector, ETFs

By Max ChenMay 16, 2016

Equity ETFs

Resisting the Temptation of Biotech ETFs

By Brenton GarenMay 16, 2016

Equity ETFs

A Biotech ETF Proving Immune to Hawkish Fed Policy Changes

By Brenton GarenMay 4, 2016

Equity ETFs

Hit The Lab With These 17 Biotech ETFs

By Tom LydonMay 2, 2016

Alternative ETFs

Capitalizing on the Biotech Rebound with Leveraged ETFs

By Max ChenApril 18, 2016

Equity ETFs

Believing in the Biotech ETF Bounce

By Tom LydonApril 13, 2016

Equity ETFs

Silver Lining for Biotechnology ETFs After Pfizer Calls off Allergan Deal

By Max ChenApril 6, 2016

Equity ETFs

More Good Technical News for Biotech ETFs

By Brenton GarenApril 5, 2016

Featured

Pharmacyclics Takeover Shines a Light on a new Biotech ETF

By Todd ShriberMarch 5, 2015